- Brand names:
- Pharmaceutical Company:
- Condition/Indication: RSV-confirmed lower respiratory tract disease
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 432KB)
Respiratory Syncytial Virus Vaccine – July 2024
Respiratory Syncytial Virus Vaccine; Powder and suspension for injection (0.5 mL); Arexvy®
Last updated
30 May 2025